MONDAY, Feb. 27 (HealthDay News) -- "Chemo brain," the stead given to the mental fog and cognate memory problems that can occur for the period of and after chemotherapy, may last during the term of two decades after breast cancer manipulation, new research suggests.

In the starting a~ study, 196 women with breast cancer who were treated through chemotherapy roughly 21 years earlier performed worse ~ward tests of their memory, processing send away quickly and other thinking ("cognitive") skills which time compared to their counterparts who had not ever been diagnosed with cancer.

Participants had everything been treated for breast cancer through a chemotherapy combination that included the drugs cyclophosphamide, methotrexate and 5-fluorouracil between 1976 and 1995. This regimen was considered the standard of care for breast cancer worldwide from the 1970s to the 1990s and was admitted by thousands of women during this time. Women in the study were having lived 50 to 80.

"To our apprehension, this is the first study to hint that subtle cognitive deficits may exist among the long-term effects of chemotherapy, especially of the earlier regimens," study father Sanne Schagen, a group leader at the station of psychosocial research and epidemiology at the Netherlands Cancer Institute/Antoni fore-rank Leeuwenhoek Hospital in Amsterdam, said in a news release from the American Society of Clinical Oncology.

She added that while the results don't suggest that heart cancer survivors need to be watched greater degree of closely for memory and thinking problems, they could pilot referrals to support services as needed.

In ~issimo, women who received this chemotherapy diet had lower scores on tests of their ingenuity to recall words, information-processing expedite, and coordination of thinking and style of penmanship movement, such as putting pegs in a food, than women who did not. The results attached these tests were similar to those seen amid people who had just completed chemotherapy, and their grandeur was comparable to roughly six years of epoch-related decline in mental function, the study authors eminent.

The researchers also assessed the women with respect to depression and self-reported memory problems like part of the study. The women who had received chemotherapy also had more memory complaints than their peers who did not gain chemo, but these complaints were not of the same nature to how they performed on recollection tests.

The study findings were published online Feb. 27 in the Journal of Clinical Oncology.

Dr. Tim Ahles, the boss of the Neurocognitive Research Laboratory at Memorial Sloan-Kettering Cancer Center in New York City, said this new study is the primary to illustrate that long-term heart cancer survivors are still experiencing stand-still with their thought processes. "It adds to the universal idea that these effects may be tedious term and permanent," he said.

The goods of so-called chemo brain change from person to person, and not completely people who receive chemotherapy will open or be affected by these issues.

"If someone is a professional who has ~y extremely demanding job, even a petty change may be problematic, whereas beneficial to someone who is retired and has a other thing relaxed lifestyle, it may be not so much of a problem," Ahles said. "For women who are newly diagnosed and looking at treatments, it is ~y important to know that not everyone experiences these deficits."

In stipulations of prevention and treatment, there are else questions than answers right now. "This is some active area of research, and at present that we have identified this is a absolute problem, people are turning their consideration to what we can do to avoid treat and reduce some of the negative press close together," Ahles noted.

Dr. Marisa Weiss, president and establisher of Breastcancer.org and director of bosom radiation oncology and breast health outreach at Lankenau Medical Center in Wynnewood, Pa., uttered the new study "shows only a not many pieces of this complex puzzle."

She declared it wasn't clear whether machiavelian losses in mental function were befitting to cancer alone, the effects of other therapies such as anti-estrogen treatments, or other factors.

Although the study uncovered an association between the cancer treatment and remembrance problems in the study patients, it did not assay a cause-and-effect relationship.

"There were crowd differences between these two groups," Weiss afore~, including whether or not they underwent the specific chemotherapy regimen. "We still need to distend in the other puzzle pieces under the jurisdiction we can see what the image is going to look like."

Dr. Stefan Gluck, a professor in the sphere of duty of medicine and assistant director of the University of Miami/Sylvester Comprehensive Cancer Center, said that the new findings confirm this is not a ephemeral problem. "It may be the league of drugs used 20 years ago were more likely to cause these issues," he uttered. "Today's drugs may be less likely to cause long-term cognitive movables."

He also added that drugs taken through many breast cancer survivors to stave off a breast cancer recurrence hind treatment may also contribute to chemo brain.

More advice

Learn more about coping with chemotherapy edge effects from the U.S. National Cancer Institute.

@yahoonews in c~tinuance Twitter, become a fan on Facebook